In a world where oncology is dominated by chemicals and radiation, Novocure is doing something radical: fighting cancer with electricity. Their Tumor Treating Fields (TTFields) therapy uses electric fields to disrupt cancer cell division, and their website is the digital front door to this $545M revolution.

"They're not just building a biotech company—they're building an entire category where cancer treatment meets physics."

The keyword strategy reveals their precision targeting. 'Novocure' dominates with 2,070 monthly searches, while 'TTFields Novocure' (400 searches) shows growing awareness of their specific technology. The presence of 'Novocure Schweiz' (160 searches) signals international expansion, while 'Novocure thyroid cancer' (200 searches) indicates they're capturing disease-specific research intent. This isn't accidental—it's a carefully calibrated content strategy that meets patients where they are in their research journey.

• TTFields therapy is FDA-approved for glioblastoma and mesothelioma, with ongoing trials for 10+ other cancers
• Their 2,064 employees are focused on clinical trials, not just digital presence—quality over quantity in hiring
• The $875M funding round shows investor confidence in their physics-based approach to oncology
• Their 34.6% traffic from undefined sources suggests strong direct/organic channels that analytics can't fully track